 Windtree Therapeutics Inc NASDAQ: WINT announced results from its Phase 2 study of lucinactant KL4 surfactant for severe COVID-19 associated acute respiratory distress syndrome ARDS and lung injury. The Phase 2 trial was designed to assess reconstituted lyophilized lucinactant. 